Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18975556 | 0.81 | ALDH1A1 (0.46) | TP53GAASMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL14417074 | 0.80 | TP53 (0.50) | TP53GAASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL28949785 | 0.77 | SMN1; SMN2 (0.48) | TP53GAASMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL3281160 | 0.77 | ALDH1A1 (0.42) | TP53GAASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL12465585 | 0.77 | TP53 (0.50) | TP53GAASMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL14673386 | 0.76 | TP53 (0.49) | TP53GAASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL18975573 | 0.74 | PADI1 (0.42) | TP53GAASMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL14067030 | 0.74 | TP53 (0.55) | TP53GAASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10516690 | 0.74 | SMN1; SMN2 (0.60) | TP53GAASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7283908 | 0.73 | TP53 (0.50) | TP53GAASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021451-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2021-06-01 | — | — | US | disclosed |
| EP-3386953-B1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| US-20200325108-A1 | CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2020-10-15 | — | — | US | disclosed |
| US-10781188-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2020-09-22 | — | — | US | disclosed |
| WO-2017098038-A1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021451-B2 | Contrast agents | SLC39A14, ABCB7, SLC40A1 | TP53 3417/4885GAA 2344/4885SMN1; SMN2 1334/4885 |
| US-20200325108-A1 | CONTRAST AGENTS | SLC39A14, ABCB7, SLC40A1 | TP53 3417/4885GAA 2344/4885SMN1; SMN2 1334/4885 |
| US-10781188-B2 | Contrast agents | SLC39A14, ABCB7, SLC40A1 | TP53 3417/4885GAA 2344/4885SMN1; SMN2 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.